/home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
">
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
Warning: Attempt to read property "cat_name" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
Design Automation Conference 2019 Exhibitor Profiles
![](https://i2.wp.com/picante.today/wp-content/uploads/2019/05/businessWireLogo-1.jpg?fit=150%2C150&ssl=1)
LAS VEGAS–(BUSINESS WIRE)–lt;a href=”https://twitter.com/hashtag/56DAC?src=hash” target=”_blank”gt;#56DAClt;/agt;–The 56th Design Automation Conference runs June 2 – 6, 2019
at the Las Vegas Convention Center.
Business Wire is the official
news distribution partner for DAC 2019. Exhibitor profiles from
the conference are listed below.
***
Company: | Achronix Semiconductor Corporation |
Booth: | 861 |
Web: | https://www.achronix.com |
Achronix Semiconductor Corporation is a privately held, fabless semiconductor corporation based in Santa Clara, California and offers high-performance FPGA and embedded FPGA (eFPGA) solutions. Achronix’s history is one of pushing the boundaries in the high-performance FPGA market. Achronix offerings include programmable FPGA fabrics, discrete high-performance and high-density FPGAs with hardwired system-level blocks, datacenter and HPC hardware accelerator boards, and best-in-class EDA software supporting all Achronix products. |
|
Company: | AMIQ EDA srl. |
Booth: | 854 |
Web: | www.dvteclipse.com |
AMIQ EDA provides tools – DVT Eclipse IDE, DVT Debugger Add-On, Verissimo Linter, and Specador Documentation Generator – that enable design and verification engineers increase the speed and quality of new code development, simplify legacy code maintenance, accelerate language and methodology learning, and improve source code reliability. Working with 100+ companies in 30+ countries, AMIQ EDA is recognized for its high quality products and customer service responsiveness. |
|
Company: | AnaGlobe Technology, Inc. |
Booth: | 934 |
Web: | http://www.anaglobe.com |
AnaGlobe is a Taiwanese EDA company, has 2 major layout platforms, THUNDER & GOLF. THUNDER is a versatile layout integration platform to support heavy layout handling efforts from post P&R, IP merge automation & management, physical ECO verification (LVL, connectivity, etc.), DRC/LVS debugging interface, and even (in-line inspection) defect-to-layout mapping, failure analysis and chip-package integration (fanout, interposer and substrate routing, pins connectivity, etc.). |
|
GOLF is a custom layout platform with a simple yet GUI-mode powerful PCell Designer for diversified applications. PCells are easily created, previewed and debugged by PCell Designer. |
|
AnaGlobe differentiates product to satisfy specific and individual user requests. |
|
Company: | Breker Verification Systems |
Booth: | 611 |
Web: | https://brekersystems.com/ |
Breker Verification Systems will demonstrate at DAC its portfolio of Portable Stimulus solutions, a standard means to specify verification intent and behaviors reusable across target platforms. Demos will highlight how a graph-based verification and the synthesis approach enables development of powerful test sets from abstract scenario models. Its Trek Portable Stimulus Portfolio is Graph-based to make complex scenarios comprehensible, Portable, eliminating test redundancy across the verification process, and Shareable to foster team communication and reuse. Intelligent Testbench tools and apps allows synthesis of high-coverage, powerful test cases for deployment into a variety of UVM to SoC verification environments. |
|
DAC attendees can schedule demonstrations at https://brekersystems.com/dac/. |
|
Company: | Cadence Design Systems, Inc. |
Booth: | 915 |
Ticker Symbol & Exchange: | NASDAQ: CDNS |
Web: | www.cadence.com |
Cadence enables electronic systems and semiconductor companies to create the innovative end products that are transforming the way people live, work and play. Cadence software, hardware and semiconductor IP are used by customers to deliver products to market faster. The company’s System Design Enablement strategy helps customers develop differentiated products—from chips to boards to systems—in mobile, consumer, cloud datacenter, automotive, aerospace, IoT, industrial and other market segments. Cadence is listed as one of Fortune Magazine’s 100 Best Companies to Work For. Learn more at cadence.com. |
|
Company: | Coventor, A Lam Research Company |
Booth: | 835 |
Web: | www.coventor.com |
Coventor® is the market leader in automated solutions for developing semiconductor process technology, as well as micro-electromechanical systems (MEMS). Coventor serves a worldwide customer base of integrated device manufacturers, memory suppliers, fabless design houses, independent foundries, and R&D organizations. Its SEMulator3D modeling and analysis platform is used for fast and accurate ‘virtual fabrication’ of advanced manufacturing processes, allowing engineers to understand manufacturing effects early in the development process and reduce time-consuming and costly silicon learning cycles. Its CoventorMP MEMS design platform is used to develop MEMS-based products for automotive, aerospace, industrial, defense, and consumer electronics applications. The company is headquartered in Cary, North Carolina, with development and sales offices worldwide. |
|
Company: | Defacto Technologies |
Booth: | 667 |
Web: | www.defactotech.com |
After a first success on moving traditional DFT checks to RTL, Defacto shifted its focus, 10 years ago, on providing SoC design solutions to help reaching aggressive PPA requirements cost-effectively. Defacto has proven the effectiveness of STAR as a design platform for large SoCs. |
|
By adopting Defacto’s STAR design solutions, major semiconductor companies are continuously moving from traditional and painful SoC design tasks to the Defacto’s joint “Build & Signoff” design methodology. The related ROI has been proven for hundreds of projects. |
|
Company: | Design And Reuse |
Booth: | 329 |
Web: |
https://www.design-reuse.com, http://www.design-reuse-embedded.com, www.design-reuse.cn |
Founded in 1997, D&R became the worldwide leader as a B2B portal in the IP/SoC field with its community of 42,000 registered users, 75,000 Absolute Unique Visitors/Month, 18,000 daily updated IP/SOC products, and news broadcast to 27,000 subscribers. |
|
Based on more than 20 years experience, D&R sells IPMSTM: a Java/XML multi-application, configurable platform, offering a comprehensive solution for IP management including smart IP delivery and smart computerized contract support, as well as an unique intelligent software tool license management solution providing user behavior profiling, and cost sharing, leading to well informed business decision making. |
|
Company: | EDDR Software |
Booth: | 633 |
Web: | www.eddrs.com |
EDDR Software is a company that works with customers and partners in order to help ENGINEER, DESIGN, DEVELOP, and RESEARCH solutions for barriers created by technology and software in their business. EDDRS also helps bridge gaps that may arise with changing technologies and requirements. EDDRS has tools to help clients produce products for their customers more efficiently and with higher performance. Check out some of them at https://www.eddrs.com/pg/products. |
|
Company: | Faraday Technology Corporation |
Booth: | 1012 |
Ticker Symbol & Exchange: | TWSE: 3035 |
Web: | https://www.faraday-tech.com |
Faraday Technology Corporation (TWSE: 3035) is a leading fabless ASIC and silicon IP provider. From specification level to GDSII-in, our flexible business engagement model allows customers to check-in at various design phases in maximizing ASIC implementation efficiency. |
|
Faraday’s comprehensive IP portfolio and best-in-class IP customization service have enabled customers’ products to address various applications and market segments effortlessly. |
|
Since 1993, Faraday has been cooperating with top-tier suppliers of IP, EDA, manufacturing, packaging, and testing, completing more than 2,200 tapeouts resulting in hundreds of millions chips shipped worldwide a year. |
|
Company: | Menta |
Booth: | 626 |
Web: | www.menta-efpga.com |
For ASIC and SoCs designers who need fast, right-the-first time design and fast time to volume, Menta is the proven eFPGA pioneer whose design-adaptive standard cells based architecture and state-of-the-art tool set provides the highest degree of design customization, best-in-class testability and fastest time-to-volume for SoC design targeting any production node at any foundry. |
|
Company: | OneSpin Solutions |
Booth: | 308 |
Web: | www.onespin.com |
OneSpin will feature at DAC its full complement of certified IC integrity verification solutions for building functionally correct, safe, secure and trusted integrated circuits. Solutions are based on OneSpin’s widely used formal verification technology and assure the integrity of SoCs, ASICs and FPGAs. Partners include leaders worldwide in automotive and industrial applications; defense; avionics; artificial intelligence and machine learning; consumer electronics; and communications. Its advanced solutions are well-suited for developing heterogeneous computing platforms, using programmable logic, and designing and integrating processor cores, such as RISC-V. OneSpin’s customer-oriented commitment is fundamental to its growth and success. |
|
Connect with OneSpin at: | |
Twitter: https://twitter.com/OneSpinSolution | |
LinkedIn: https://www.linkedin.com/company/onespin-solutions | |
Facebook: https://www.facebook.com/OneSpinSolutions | |
Company: | OpenText |
Booth: | 1117 |
Ticker Symbol & Exchange: | OTEX NASDAQ |
Web: | https://www.opentext.com/ |
OpenText Connectivity products, formerly Hummingbird provides web-based remote access and virtual desktop infrastructure (VDI) software for UNIX, Linux and Windows applications. |
|
OpenText Exceed TurboX (ETX) is designed from the ground up to enable session resilience and local-like responsiveness for graphically demanding applications, even over high latency WAN connections. |
|
Many leading semiconductor companies are successfully using ETX to achieve blazing fast access from anywhere to chip layout applications and other EDA tools. |
|
Company: | PRO DESIGN Electronic GmbH |
Booth: | 635 |
Web: | https://www.profpga.com/ |
PRO DESIGN is a leading provider of FPGA-based Prototyping systems. PRO DESIGN’s product family proFPGA is a very flexible high-performance FPGA system which is mainly used for ASIC Prototyping and pre-silicon software development. The modular concept of the proFPGA system, consisting of different motherboards, FPGA modules, daughter boards and interconnects allows the user to adjust it for almost any type of application. PRO DESIGN is offering FPGAs produced by XILINX and Intel, those can be Mix and Matched on one proFPGA System. |
|
Company: | SANKALP SEMICONDUCTOR |
Booth: | 510 |
Web: | www.sankalpsemi.com |
Sankalp Semiconductor offers an integrated portfolio of services and solutions to its customers in key semiconductor domains including analog & mixed signal, digital, high-speed physical interface IP, Embedded Memory Compiler, IOs & EDA modeling. Sankalp is a preferred semiconductor design service partners to multiple Fortune 500 companies in the Automotive, Consumer, Networking, Wireless, IoT, Medical electronics & Foundry space. The company enables its customers deliver first time right silicon & engage with product engineering teams across the globe to design SoCs. Sankalp is based in Palo Alto, California & Hubli, India with offices in USA, India, Canada, Germany, Malaysia and Japan. |
|
Company: | Sigasi |
Booth: | 646 |
Web: | www.sigasi.com |
Sigasi radically redefines digital design. Our design entry tool Sigasi Studio drastically improves hardware designer productivity by helping to write, inspect and modify digital circuit designs in the most intuitive way. Advanced features such as intelligent autocompletes and code refactoring, make VHDL, Verilog and SystemVerilog design easier, more efficient. |
|
Sigasi, has formed partnerships with FPGA and EDA companies including Altera, Xilinx and Aldec. The Sigasi Studio XL platform is used worldwide by industry leaders in the fields of healthcare, consumer electronics, industrial automation, telecom, aerospace and defense. |
|
Company: | Silicon Creations |
Booth: | 525 |
Web: | www.siliconcr.com |
Silicon Creations is focused on providing world-class silicon intellectual property (IP) for precision and general-purpose timing (PLLs), SerDes and high-speed differential I/Os. Silicon Creations’ IP is in production from 7 to 180-nanometer process technologies. With a complete commitment to customer success, its IP has an excellent record of first silicon to mass production in customer designs. Silicon Creations, founded in 2006, is self-funded and growing. The company has development centers in Atlanta, Ga., and Krakow, Poland, and worldwide sales representation. For more information, visit www.siliconcr.com. |
|
Company: | SmartDV Technologies |
Booth: | 514 |
Web: | www.Smart-DV.com |
SmartDV![]() Verification Intellectual Property (VIP), will be in DAC Booth #514 with demonstrations of Smart ViPDebug ![]() that reduces debug time by rapidly identifying violations. Also highlighted will be SmartDV’s Compute Express Link (CXL) and Ethernet Time-Sensitive Networking (TSN) VIP solutions, along with its extensive VIP portfolio used in hundreds of networking, storage, automotive, bus, MIPI and display chip projects. SmartDV’s VIP is compatible with all verification languages, platforms and methodologies supporting all simulation, emulation and formal verification tools used in a coverage-driven chip design verification flow. |
|
DAC attendees can schedule demonstrations through SmartDV’s online scheduler: http://smart-dv.com/dac.html. |
|
Company: | Univa |
Booth: | 1233 |
Web: | www.univa.com |
Univa is the leading innovator of workload management solutions that optimize throughput and performance of applications, containers, and services. Univa manages workloads automatically by maximizing shared resources and enabling enterprises to scale compute resources across on-premise, hybrid and cloud infrastructures. Univa’s solutions help hundreds of companies to manage thousands of applications and run billions of tasks every day to obtain actionable insights and achieve faster time-to-results. Univa is headquartered in Chicago, with offices in Canada and Germany. |
|
Company: | Verific Design Automation |
Booth: | 638 |
Web: | www.verific.com |
At DAC, Verific will celebrate 20 years as the leading provider of SystemVerilog, Verilog, VHDL and UPF Parser Platforms, used by EDA, FPGA and semiconductor companies worldwide. Verific’s R&D and applications staff will explain how its SystemVerilog, VHDL and UPF parsers, as well as its “Verific with INVIO” platform enable project groups to develop advanced EDA products quickly and cost effectively. Demos of the INVIO platform will illustrate the ways in which its SystemVerilog- and VHDL-language agnostic Python and C++ APIs simplify and streamline a Verific user’s design environment to accelerate tool development. |
|
Engage with Verific at: | |
Email: info@verific.com | |
LinkedIn: https://www.linkedin.com/company-beta/810695 |
***
Qualified members of the press please note the following important
information.
Exhibitor News:
http://www.tradeshownews.com/events/design-automation-conference-2019/
Press Information:
https://dac.com/content/press-registration
About Business Wire
Business Wire, a Berkshire
Hathaway company, is the global leader in news
release distribution and regulatory
disclosure. Investor relations, public relations, public policy and
marketing professionals rely on Business Wire for secure and accurate
distribution of market-moving news and multimedia. Founded in 1961,
Business Wire is a trusted source for news organizations, journalists,
investment professionals, and regulatory authorities, delivering news
directly into editorial systems and leading online news sources via its
multi-patented NX Network. Business Wire has 18 newsrooms worldwide to
meet the needs of communications professionals and news media.
Learn more at www.businesswire.com.
Follow us on Twitter @businesswire.
Contacts
Jim Liebenau
+1.310.820.9473
Twitter: @tradeshownews
![](https://grassnews.net/wp-content/uploads/2019/03/Grassnews-600px.png)
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493
Warning: Attempt to read property "cat_ID" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493
Innocan
Innocan Pharma Submits Investigational New Animal Drug Application to FDA’s Veterinary Center
![innocan-pharma-submits-investigational-new-animal-drug-application-to-fda’s-veterinary-center](https://grassnews.net/wp-content/uploads/2024/07/61449-innocan-pharma-submits-investigational-new-animal-drug-application-to-fdas-veterinary-center.jpg)
HERZLIYA, Israel and CALGARY, AB, July 26, 2024 /PRNewswire/ — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (“Innocan” or the “Company”), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that the FDA’s Center for Veterinary Medicine (CVM) has granted the Company a sponsor fee waiver and assigned an Investigational New Animal Drug (INAD) number for its LPT-CBD (Liposome Platform Technology-Cannabidiol) product. This represents a significant step for the Company, as an INAD designation facilitates correspondence and data exchange with CVM to support LPT-CBD development as a new veterinary drug.
The Company further announced that following the assessment of LPT-CBD’s scientific package, the CVM recognized Innocan’s contribution to pursuing innovative animal drug products and technology and granted the company a sponsor fee waiver for fiscal year 2024.
Innocan’s LPT-CBD is a proprietary drug delivery platform designed to provide prolonged-release CBD for chronic pain and well-being management in animals. Over the past year, repeated administration of LPT-CBD in dogs and other animals has demonstrated both efficacy and tolerability, providing sufficient evidence for the INAD application.
“We are thrilled by CVM’s response,” said Prof. Chezy Barenholz, CSO of Innocan Pharma. “The granted INAD will allow us to advance the investigational studies of LPT-CBD and share knowledge to support future discussions with CVM on LPT-CBD’s development plan. Moreover, the fee waiver, granted by CVM, supports our development and pursuit of innovative animal drug products and technology, further validating our approach and potential impact in veterinary medicine.”
Dr. Eyal Kalo, R&D Director at Innocan, added, “LPT-CBD is a unique technology that has proven itself worthy of the INAD fee waiver granted by CVM. This will streamline our efforts to deliver a unique solution for chronic pain management to the animal market.”
About Innocan Pharma:
Innocan is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies comprises with cannabinoids science, to treat various conditions to improve patients’ quality of life. This segment involves two drug delivery technologies: (i) LPT CBD-loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the blood stream. The LPT delivery platform research is in the preclinical trial phase for two indications: Epilepsy and Pain Management. In the Consumer Wellness segment, Innocan develops and markets a wide portfolio of innovative and high-performance self-care products to promote a healthier lifestyle. Under this segment Innocan has established a Joint Venture by the name of BI Sky Global Ltd. that focuses developing on advanced targeted online sales. https://innocanpharma.com/
Contact Information:
For Innocan Pharma Corporation:
Iris Bincovich, CEO
+1 5162104025
+972-54-3012842
+442037699377
info@innocanpharma.com
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Caution Regarding Forward-Looking Information
Certain information set forth in this news release, including, without limitation, the Company’s plans for human trials of its LPT-CBD platform, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. . The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of production and distribution arrangements.
Forward-looking information is subject to various risks and uncertainties that could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: global and local (national) economic, political, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and potential disruption of relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import/export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner). The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release. A comprehensive discussion of other risks that impact Innocan can be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedarplus.ca.
Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.
Logo: https://mma.prnewswire.com/media/2046271/3968398/Innocan_Pharma_Corporation_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/innocan-pharma-submits-investigational-new-animal-drug-application-to-fdas-veterinary-center-302207435.html
Cannabis
Verano Announces the Opening of Zen Leaf Fairless Hills, the Company’s Newest Affiliated Dispensary in Pennsylvania, in Prime New Location
![](https://grassnews.net/wp-content/uploads/2024/07/verano-announces-the-opening-of-zen-leaf-fairless-hills-the-companys-newest-affiliated-dispensary-in-pennsylvania-in-prime-new-location.gif)
- Zen Leaf Fairless Hills, the Company’s newest affiliated dispensary in Pennsylvania, relocated from its former home in Chester to 203 Lincoln Highway, a busy thoroughfare with daily traffic of over 17,000 vehicles per day1
- As the first medical cannabis dispensary in the city, Zen Leaf Fairless Hills will offer an elevated experience for area patients, including increased convenience and accessibility with numerous point-of-sale stations and kiosks for seamless in-store browsing and ordering
- Verano’s active operations span 13 states, comprised of 142 dispensaries and 13 cultivation and processing facilities with more than 1 million square feet of cultivation capacity
CHICAGO, July 26, 2024 (GLOBE NEWSWIRE) — Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNOF) (“Verano” or the “Company”), a leading multi-state cannabis company, today announced the opening of Zen Leaf Fairless Hills in Pennsylvania on Friday, July 26th, following a ceremonial ribbon cutting at 11 a.m. local time. Zen Leaf Fairless Hills is located at 203 Lincoln Highway and will be open Monday through Saturday from 9 a.m. to 8 p.m. and Sunday from 10 a.m. to 6 p.m. local time.
The dispensary is located in Bucks County, the fourth largest county in the Commonwealth with a total population of over 630,0002 residents. To increase accessibility and convenience, Zen Leaf Fairless Hills features large in-store kiosks and numerous point-of-sale stations to enhance the browsing and ordering experience for patients. To celebrate the grand opening of Zen Leaf Fairless Hills and following a ceremonial ribbon cutting, patients will be greeted with complimentary deals and doorbusters on featured branded products.
“We are excited to bring the Zen Leaf experience to local patients in Fairless Hills, where our talented team members will continue to deliver hospitality-driven care and top-quality products for local patients,” said George Archos, Verano Founder and Chief Executive Officer. “As the Pennsylvania medical cannabis patient population continues to grow, we are grateful for the opportunity to deepen our roots in Bucks County at our newest Zen Leaf location in the Commonwealth, and look forward to providing a warm and welcoming environment for current and future patients.”
Zen Leaf Fairless Hills adds another convenient outlet for Philadelphia area patients, and solidifies Verano’s footprint in the state as one of the Company’s 18 affiliated Pennsylvania dispensaries. Verano’s Pennsylvania operations also include a state-of-the-art 62,000 square foot cultivation and processing facility in Chester, where the Company produces its signature Verano Reserve flower and Troches, concentrates and vapes; (the) Essence and Savvy flower and extracts; and Avexia RSO cannabis oil and topicals. For additional convenience and accessibility, patients can choose to order ahead at ZenLeafDispensaries.com for express in-store pickup.
About Verano
Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNOF), one of the U.S. cannabis industry’s leading companies based on historical revenue, geographic scope and brand performance, is a vertically integrated, multi-state operator embracing a mission of saying Yes to plant progress and the bold exploration of cannabis. Verano provides a superior cannabis shopping experience in medical and adult use markets under the Zen Leaf™ and MÜV™ dispensary banners, including Cabbage Club™, an innovative annual membership program offering exclusive benefits for cannabis consumers. Verano produces a comprehensive suite of high-quality, regulated cannabis products sold under its diverse portfolio of trusted consumer brands including Verano™, (the) Essence™, MÜV™, Savvy™, BITS™, Encore™, and Avexia™. Verano’s active operations span 13 U.S. states, comprised of 13 production facilities with over 1,000,000 square feet of cultivation capacity. Learn more at Verano.com.
Contacts:
Media
Verano
Steve Mazeika
VP, Communications
Steve.Mazeika@verano.com
Investors
Verano
Julianna Paterra, CFA
VP, Investor Relations
Julianna.Paterra@verano.com
Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans, strategies, or objectives, many of which, by their nature, are inherently uncertain and outside of the Company’s control. Generally, such forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “future”, “scheduled”, “estimates”, “forecasts”, “projects,” “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases, or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved”. Forward-looking statements involve and are subject to assumptions and known and unknown risks, uncertainties, and other factors which may cause actual events, results, performance, or achievements of the Company to be materially different from future events, results, performance, and achievements expressed or implied by forward-looking statements herein, including, without limitation, the risk factors described in the Company’s annual report on Form 10-K for the year ended December 31, 2023, its quarterly report on Form 10-Q for the quarter ended March 31, 2024 and any subsequent quarterly reports on Form 10-Q, in each case, filed with the U.S. Securities and Exchange Commission at www.sec.gov. The Company makes no assurances and cannot predict the outcome of all or any part of the on-going litigation with Goodness Growth referenced in this press release, including whether the Company will prevail on its Notice of Application and its counterclaim, or whether Goodness Growth will prevail on its claim for damages against the Company. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake to update any forward-looking information or forward-looking statements that are contained or referenced herein, except as may be required in accordance with applicable securities laws. All subsequent written and oral forward-looking information and statements attributable to the Company or persons acting on its behalf is expressly qualified in its entirety by this notice regarding forward-looking information and statements.
###
1 Pennsylvania Department of Transportation
2 United States Census Bureau
Cannabis
Unlocking New Horizons in Health: TNR, The Niche Research Reveals the Transformative Power of Minor Cannabinoids
![](https://grassnews.net/wp-content/uploads/2024/07/unlocking-new-horizons-in-health-tnr-the-niche-research-reveals-the-transformative-power-of-minor-cannabinoids.gif)
Wilmington, Delaware, July 25, 2024 (GLOBE NEWSWIRE) — Minor cannabinoids refer to the lesser-known compounds found in the cannabis plant, distinct from the well-known THC (tetrahydrocannabinol) and CBD (cannabidiol). While THC and CBD dominate the market, minor cannabinoids such as CBG (cannabigerol), CBC (cannabichromene), and CBN (cannabinol) are gaining attention for their potential therapeutic benefits. These compounds are extracted from both marijuana and hemp plants, with varying legal restrictions depending on their THC content. The minor cannabinoids market is poised for significant growth, driven by increasing consumer awareness and demand for alternative health and wellness products. As regulatory environments around cannabis products evolve, companies are exploring the potential of minor cannabinoids in various applications, including pharmaceuticals, nutraceuticals, cosmetics, and food and beverages.
Minor cannabinoids are being researched for their potential therapeutic effects, including anti-inflammatory, analgesic, and neuroprotective properties. This versatility facilitates product diversification in various industries. Companies are investing in research and development to create novel formulations and delivery methods for minor cannabinoids. This includes nano-emulsions, encapsulation technologies, and controlled-release systems to enhance bioavailability and efficacy. For example, in January 2022, CBDA + CBGA Tincture a new product was launched by Hometown Hero CBD. This 30ml tincture contains 600mg each of CBGA, CBDA, CBG, and CBD. Derived from hemp, the cannabinoids in this tincture comply with legal requirements across all 50 states in the USA. There is an increasing consumer preference for natural as well as plant-based remedies, which in turn is driving the demand for cannabinoid-infused products. This trend is particularly strong among younger demographics seeking alternatives to traditional pharmaceuticals. Evolving regulatory frameworks, particularly in regions like North America and Europe, are creating opportunities for legal market expansion. Regulatory clarity is crucial for market participants to navigate compliance and market entry.
Global Minor Cannabinoids Market: Key Datapoints
Market Value in 2023 |
US$ 17.8 Bn |
Market Value Forecast by 2034 |
US$ 42.3 Bn |
Growth Rate
|
8.2% |
Historical Data
|
2016 – 2022 |
Base Year
|
2023 |
Forecast Data
|
2024 – 2034 |
Increasing consumer interest in health and wellness products, coupled with the perceived therapeutic benefits of cannabinoids, is a major driver of market growth. Progressive cannabis legalization in various parts of the world, including the United States and parts of Europe, is expanding the addressable market for minor cannabinoids. Significant investments in research and development by pharmaceutical and biotechnology companies are accelerating product innovation and clinical trials. The market remains fragmented with opportunities for new entrants and niche players to introduce specialized products catering to specific consumer needs.
The COVID-19 pandemic initially disrupted supply chains and retail channels for minor cannabinoids products. However, the crisis also underscored the importance of health and wellness, leading to increased interest in natural remedies, including cannabinoids. As economies recover, the market is expected to rebound stronger.
The geopolitical tensions, such as the Russia-Ukraine conflict, have also affected global markets, including the minor cannabinoids sector. Fluctuating currency values, supply chain disruptions, and geopolitical uncertainty have impacted production and distribution channels. However, the long-term impact will depend on geopolitical developments and their influence on global trade and regulatory environments.
The minor cannabinoids market presents significant opportunities for growth and innovation, driven by evolving consumer preferences, regulatory advancements, and expanding research initiatives. Companies that can navigate regulatory complexities, invest in research and development, and respond to shifting consumer trends are well-positioned to capitalize on this emerging market. As the market matures, collaboration across sectors and regions will be crucial in unlocking the full potential of minor cannabinoids in various industries worldwide.
Global Minor Cannabinoids Market: Key Takeaways of the Report
- Cannabigerol (CBG) segment by product type is expected to grow at a CAGR of 6.7% in the minor cannabinoids market due to increasing research highlighting its potential therapeutic benefits, including anti-inflammatory, antimicrobial, and neuroprotective properties. As consumer awareness grows and regulatory environments become more favorable, there is heightened interest in CBG-based products for their diverse health applications, ranging from skincare to pharmaceutical formulations, driving sustained market demand and expansion.
- Pharmaceutical segment by application, leads the minor cannabinoids market with a significant revenue share of 35.8% owing to growing recognition of cannabinoids’ potential in therapeutic applications. Cannabinoids like CBD, CBG, and others show promise in treating conditions such as epilepsy, chronic pain, and anxiety disorders, backed by increasing clinical research and favorable regulatory developments. Pharmaceutical companies are investing heavily in cannabinoid-based drug development, driving market growth as they seek to capitalize on these compounds’ efficacy and market potential in addressing unmet medical needs.
- In 2023, Latin America is anticipated as fastest growing region in the global minor cannabinoids market due to evolving regulatory landscapes favoring cannabis legalization and cultivation. This shift is fostering a burgeoning industry infrastructure for cannabis extraction and product development. Additionally, increasing consumer acceptance of cannabinoid-based products for medicinal and wellness purposes is driving market expansion. With a vast potential consumer base and supportive regulatory frameworks, Latin America presents significant growth opportunities for companies seeking to enter or expand within the minor cannabinoids market.
Key Development:
- In December 2023, Rare Cannabinoid Company introduced Uplift Gummies infused with THC and THCV. These gummies combine the relaxing properties of Delta-9-THC with the energizing and appetite-controlling effects of CBD and THCV.
- In October 2022, High Tide Inc., a cannabis retailer, announced that its Colorado-based subsidiary, NuLeaf Naturals, had launched plant-based softgels and full-spectrum multicannabinoid oil in Manitoba. The products feature CBC, CBD, CBG, Delta-9 tetrahydrocannabinol (Delta 9), and CBN.
Browse Related Category Reports
Global Minor Cannabinoids Market:
- Aurora Europe GmbH
- BulKanna
- CBD. INC.
- Fresh Bros Hemp Company
- GCM Holdings, LLC (Global Cannabinoids)
- GenCanna.
- High Purity Natural Products.
- Laurelcrest
- Mile High Labs
- PBG Global
- Rhizo Sciences
- ZERO POINT EXTRACTION, LLC
- Other Industry Participants
Global Minor Cannabinoids Market
By Product Type
- Cannabigerol (CBG)
- Cannabichromene (CBC)
- Cannabinol (CBN)
- Cannabidivarin (CBDV)
- Tetrahydrocannabutol (THCB)
- Tetrahydrocannabivarin (THCV)
- Tetrahydrocannabiphorol (THCP)
- Others
By Application
- Pharmaceutical
- Pain Management
- Mental Health
- Sleep Disorders
- Anti-inflammatory
- Others
- Nutraceuticals
- Cosmetics and Personal Care
- Food and Beverages
- Others
By Region
- North America (U.S., Canada, Mexico, Rest of North America)
- Europe (France, The UK, Spain, Germany, Italy, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, The Netherlands, Luxembourg), Rest of Europe)
- Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Rest of Asia Pacific)
- Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa)
- Latin America (Brazil, Argentina, Rest of Latin America)
Consult with Our Expert:
Jay Reynolds
The Niche Research
Japan (Toll-Free): +81 663-386-8111
South Korea (Toll-Free): +82-808- 703-126
Saudi Arabia (Toll-Free): +966 800-850-1643
United Kingdom: +44 753-710-5080
United States: +1 302-232-5106
Email: askanexpert@thenicheresearch.com
Website: www.thenicheresearch.com
-
Cannabis2 weeks ago
IM Cannabis Shares Commence Trading on 6:1 Consolidated Basis
-
Cannabis2 weeks ago
Fractional Flow Reserve Market growing at a CAGR of 15.56% during the forecast period [2024-2030] – Exactitude Consultancy
-
Cannabis1 week ago
Blank Rome Bolsters Energy Industry Team in Houston and Pittsburgh with Leading Transactional Group
-
Cannabis1 week ago
Manitoba Harvest Hemp Foods and Brightseed® Introduce New Coffee and Chocolate Flavors in Organic Bioactive Fiber Supplement for Gut Health
-
Cannabis4 days ago
Europe Medical Cannabis Oil Market Set to Reach Valuation of USD 2,395.83 Million by 2032 | Astute Analytica
-
Cannabis4 days ago
Global Agricultural Textiles Market Size To Worth USD 25.02 Billion By 2033 | CAGR of 4.70%
-
Cannabis1 day ago
Unlocking New Horizons in Health: TNR, The Niche Research Reveals the Transformative Power of Minor Cannabinoids
-
Cannabis13 hours ago
Verano Announces the Opening of Zen Leaf Fairless Hills, the Company’s Newest Affiliated Dispensary in Pennsylvania, in Prime New Location